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Abstract 
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of 
excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in 
fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism 
spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with 
either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a 
score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was 
generally well-tolerated. The most common adverse events were agitation and irritability, which 
typically resolved without dose changes, and were often felt to represent spontaneous variation in 
underlying symptoms. Improvements were observed on several outcome measures in this 
exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social 
Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global 
impression scales. Placebo-controlled study of STX209 is warranted. 
Introduction 
Although the number of children and adults diagnosed with autism spectrum disorders (ASD) has 
increased over the last decade, (CDC 2012) only two pharmacologic agents (risperidone and 
aripiprazole) are FDA-approved for use in this population. These agents are indicated for the 
treatment of irritability in youth with autistic disorder. Irritability, marked by severe tantrums, 
aggression and self-injury, is common and impairing, but not a core deficit of the 
disorder.(McPheeters et al. 2011; Huffman et al. 2011) The use of these atypical antipsychotics 
targeting irritability associated with autistic disorder was based on empirical extension of their 
effects in other disorders and previous reports on use of typical (older generation) antipsychotics 
in ASD, rather than specifically on a neurobiological understanding of the pathophysiology of 
ASD. 
The development of “targeted treatments”(Geschwind 2009; Hagerman et al. 2010) for 
neuropsychiatric and neurodevelopmental disorders is a newer concept, wherein potential 
treatments are identified on the basis of a specific understanding of molecular and cellular 
pathophysiology. Although ASD has been the subject of ever increasing research, its etiologic 
heterogeneity has challenged efforts to identify a biological target for intervention (State 2010). 
One approach to this dilemma is to study single gene disorders associated with high rates of 
comorbid ASD, such as fragile X syndrome (FXS) and tuberous sclerosis (Hagerman et al. 2010). 
FXS is the most common known single gene risk for ASD, accounting for an estimated 1–3 % of 
all cases of ASD (Kumar and Christian 2009). The most extensively validated model of the 
pathophysiology of FXS is that neurobehavioral impairment results from abnormal synaptic 
plasticity, driven by excessive signaling downstream of the metabotropic glutamate receptor type 
5 (mGluR5) (Bear et al. 2004). These impairments, ranging from elevated synaptic protein 
synthesis and seizure susceptibility to abnormal dendritic spine morphology, can be rescued in 
preclinical FXS models by down-modulating mGluR5 signaling through either pharmacologic or 
genetic strategies (Krueger and Bear 2011). Even mature animals with the FXS mutation can 
show signs of pharmacological rescue by decreasing mGluR5 signaling.(Michalon et al. 2012). 
The relevance of FXS to non-syndromic (idiopathic) cases of ASD is supported by genetic studies 
of ASD, which suggest that the largest group of genes associated with non-syndromic ASD 
belongs to a network of genes that are involved in synaptic function.(Gai et al. 2012) Specific 
genes that have been suggested to be implicated include GRM5, which codes for mGluR5, and 
several genes that code for proteins involved in the signaling cascade downstream of mGluR5 
(Kelleher et al. 2012; Skafidas et al. 2012). Although findings are not uniformly consistent, 
behavioral pharmacology studies show that mGluR5 antagonists or negative allosteric modulators 
of mGluR5 rescue the impairments in social behavior that are seen in several putative mouse 
models of ASD, such as the BTBR mouse (Silverman et al. 2012), the Nlgn3- knockout mouse 
(Baudouin et al. 2012), and mice exposed prenatally to valproic acid (Gandal et al. 2010). 
Furthermore, current models of FXS and ASD posit a pathophysiologic role for an elevated 
excitatory to inhibitory (E:I) ratio in neurotransmission (Rubenstein and Merzenich 2003; 
Paluszkiewicz et al. 2011). Recent optogenetic studies in mice show that elevation of the E:I ratio 
results in the impairment of social behaviors, and that subsequent augmentation of inhibitory 
neurotransmission can reduce this impairment.(Yizhar et al. 2011) In patients with syndromic and 
idiopathic ASD, abnormally high E:I ratios may be reflected in seizure susceptibility, sensory 
hyper-responsiveness, anxiety, and increases in cortical activation, especially in the amygdala, 
when confronted with social stimuli (Watson et al. 2008; Rubenstein and Merzenich 2003). 
Another potential therapeutic agent that is being tested in FXS and ASD is STX209 (arbaclofen), 
a specific GABA-B receptor agonist. Although STX209 is not an mGluR5 antagonist, it acts 
presynaptically to reduce glutamate release (Kang et al. 2012), and may thus, by reducing 
glutamatergic activity, have a mechanism that converges with that of mGluR5 antagonists. 
Research in animal models of FXS demonstrates that STX209, like selective mGluR5 
antagonists, reduces elevated protein synthesis, susceptibility to audiogenic seizures, and 
abnormalities in dendritic spine morphology (Henderson et al. 2012). In idiopathic ASD, post-
mortem studies also have observed reductions in GABA-B receptor binding in cingulate cortex, 
fusiform gyrus, and elsewhere in the brain (Fatemi et al. 2009; Oblak et al. 2010). 
In a Phase 2 clinical trial that enrolled 63 children and adults with FXS, treatment with STX209 
was associated with improvements on the Aberrant Behavior Checklist (ABC)—FXS Social 
Avoidance scale, a subscale of the ABC that was recently factor- analyzed for potential use 
specific to the FXS population (Berry-Kravis et al. 2012). This scale consists of four highly-
correlated items that are all found in the original “Lethargy/Social Withdrawal” subscale of the 
ABC (ABC-LSW). Further post hoc analyses showed that STX209 was associated also with 
improvement on global measures and on the Vineland Adaptive Behavior Scales—Socialization 
domain in the subset of 27 subjects with more severe social impairment (as measured by the 
ABC-SW) at baseline. 
The study we now report on was designed as a preliminary investigation of whether STX209 also 
might have beneficial effects in patients with ASD not associated with FXS. While animal 
research and the clinical trial in FXS, both reviewed above, 
suggest that a GABAergic agent such as STX209 might have beneficial effects in the social 
domain, we examined a broad range of outcomes in this exploratory study. The ABC-Irritability 
subscale was chosen to be the primary outcome measure, because it is known to be sensitive to 
change in pharmacologic trials for ASD, which has not been demonstrated for any measure of 
social outcomes. 
Methods 
This study (clinicaltrials.gov identifier NCT00788073) was approved by all relevant Institutional 
Review Boards. Informed consent was provided for all subjects by their parents or legally-
authorized representative, and assent was provided by subjects, as appropriate. The study was 
sponsored by Seaside Therapeutics, Inc. 
Subjects 
This study enrolled children and adolescents, aged 6–17 years, who met DSM-IV criteria for 
either Autistic Disorder or Pervasive Developmental Disorder, Not Otherwise Specified (PDD–
NOS). Subjects also were evaluated for diagnostic corroboration using the Autism Diagnostic 
Interview-Revised (ADI-R), but no criterion score was required for entry. Subjects also were 
required to have a baseline score of 17 or greater on the ABC-Irritability subscale, and a score of 
4 (moderate) or worse on the Clinical Global Impression of Severity scale (CGI-S). Subjects were 
not permitted to enroll if they had a known genetic diagnosis that is associated with ASD (e.g., 
FXS, tuberous sclerosis, or copy number variant associated with ASD), but genetic testing was 
not performed as part of this trial. Other medical exclusion criteria included a history of seizure 
disorder, unless the subject was on a stable regimen of antiepileptic drug(s) and seizure-free for at 
least 6 months. Pregnant females were not allowed to enroll. 
Up to two concurrent psychoactive medications were allowed if dosing had been stable for at 
least 4 weeks prior to study entry, and remained stable throughout the study. Patients receiving 
antipsychotic medications were not permitted to enroll, given their significant and potentially 
confounding side effect profile, and because of their known benefits on symptoms of irritability, 
which comprised the primary outcome of the study. Use of vigabatrin, tiagabine, and riluzole also 
were prohibited, due to their potentially confounding GABA-ergic and/or glutamatergic 
mechanisms. Similarly, educational and behavioral interventions were required to be stable 
starting 3 months prior to study enrollment and to remain stable throughout the study. Regular 
school vacations were not regarded as disruptions in educational programming. 
Study Design 
The study was an eight-week, open-label trial, conducted at eight sites in the USA. After a 
screening period of up to 30 days, STX209 was started at a dose of 1 mg BID, then increased 
every 3–4 days to a maximum dose of 10 mg BID (ages 6–11 years) or 10 mg TID (ages 12–17 
years). Study visits were conducted at Weeks 2, 4, 6, and 8, with additional phone calls during 
up-titration of study drug and as needed. Planned dose increases were halted if subjects were 
“very much improved” (score of 1 on the CGI-Improvement (CGI-I) scale. If subjects did not 
tolerate their new, higher dose, then the dose was reduced to the previous tolerated level. For each 
subject, the highest dose that was associated with acceptable tolerability was declared the optimal 
tolerated dose (OTD). Subjects continued on their OTD for the remainder of the 8-week treatment 
period. After completion of assessments at the 8-week time point, subjects were tapered off of 
study drug over 1–2 weeks, or more slowly as tolerated, in very few cases. 
Assessments and Analysis 
A broad battery of efficacy assessments was administered, including the ABC, the CGI-S, the 
CGI-I, the Social Responsiveness Scale (SRS), the Children’s Yale-Brown Obsessive 
Compulsive Scale—modified for PDD (CY-BOCS-PDD), the Child and Adolescent Symptom 
Inventory-4 (CASI) Anxiety scale, the Attention Deficit Hyperactivity Disorder (ADHD) Rating 
Scale-IV, the Vineland Adaptive Behavior Scales (VABS), visual analog scales (VAS) for 3 
target behaviors nominated by the subjects’ parents or primary caregivers, and the Leiter-R Brief 
IQ score. The ABC-Irritability subscale was the primary outcome measure, chosen in alignment 
with the primary outcome used in the approval studies of risperidone and aripiprazole. Safety 
assessments included spontaneously reported adverse events (coded according to the Medical 
Dictionary for Regulatory Activities, MedDRA, version 12.0), physical examination, 
electrocardiograms (ECG), and standard clinical laboratory tests. 
All efficacy analyses reported below are from the full, intent-to-treat (ITT) study population. 
Statistical analyses included measurements from baseline and all treatment visits, using repeated 
measures analysis of variance techniques, with terms for time and age group (child vs. 
adolescent). p values reported below are for the comparison of baseline to end-of-treatment. 
Results 
Forty-six subjects underwent screening for study enrollment, and 32 (29 male) met all inclusion 
and exclusion criteria. Demographics and baseline characteristics of the subjects are provided in 
Table 1. 
Table 1 
Subject characteristics 
Total number of subjects 32 
Age 
6–11 years 12 
12–17 years 20 
Sex (M/F) 29/3 
Race (>1 response permitted) 
Caucasian 31 
African-American 1 
Other 1 
Ethnicity: non-Hispanic/Hispanic 29/3 
DSM-IV diagnosis 
Autistic disorder 27 
PDD–NOS 5 
ADI-R autistic disorder (yes/no) 29/3 
Concomitant psychoactive medication 
(any) 21 
Psychostimulants 5 
Alpha-adrenergics 6 
SSRI/SNRI 4 
Anti-epileptics 3 
IQ (mean ± standard deviation) 56 ± 22 
Twenty-five of 32 subjects completed the study, with 2 discontinuing due to adverse events (1 for 
increased impulsivity, increased aggression, and increased oppositionality; 1 for agitation). Five 
subjects discontinued for other reasons (1 withdrew consent; 1 lost to follow-up; 1 for a planned 
tonsillectomy; 1 switched directly to racemic baclofen at Week 8, rather than taper off STX209 as 
required by study protocol; and 1 at investigator’s discretion). There was 1 serious adverse event 
(worsening aggression), which occurred during the planned taper of study medication at the end 
of the treatment period. 
STX209 was generally well-tolerated. The most common adverse events were agitation (22 %), 
irritability (22 %), fatigue (16 %), psychomotor hyperactivity (16 %), insomnia (13 %) and 
diarrhea (13 %). Other events occurring in more than 5 % of the subjects are listed in Table 2. A 
large majority of the adverse events were rated as mild in severity, and resolved without dose 
changes. Most of the events reflecting potential activation (e.g., agitation, irritability, 
hyperactivity) were transient and resolved spontaneously, and were often judged to be 
manifestations of the spontaneous variability in underlying symptoms and unrelated to drug 
administration. Indeed, many subjects who were rated as globally “much improved” had transient 
events of this nature. Clinical laboratory assessments and ECGs did not show any treatment- 
associated abnormalities. 
Table 2 
Adverse events reported in ≥5 % of subjects 
Adverse event Frequency (%) 
Agitation 22 
Irritability 22 
Fatigue 16 
Psychomotor hyperactivity 16 
Diarrhea 13 
Insomnia 13 
Aggression 9 
Disturbance in attention 9 
Headache 9 
Nasopharyngitis 9 
Abdominal pain, upper 6 
Cough 6 
Decreased appetite 6 
Dizziness 6 
Streptococcal pharyngitis 6 
Self-injurious behavior 6 
Upper respiratory tract 
infection 6 
Vomiting 6 
Broad positive changes with drug treatment on a number of outcome measures were seen in the 
ITT population of this open-label trial. On the primary endpoint, the ABC-Irritability scale, 
subjects showed improvement from a baseline score of 27.0 ± 7.61 (mean ± standard deviation), 
to 17.7 ± 10.35 at Week 8 (p < 0.001). Improvements on this scale were seen at all study visits 
(Weeks 2, 4, 6, and 8), and no difference in effect was seen in the younger children compared to 
the adolescents. The magnitude of improvement increased slightly from Week 2 to 4, without 
notable change thereafter. Subjects also showed significant improvement on the ABC-
Lethargy/Social Withdrawal scale, from a score of 17.3 ± 8.18 at baseline, to 12.6 ± 9.30 at Week 
8 (p = 0.001), with improvement apparent by Week 2 (Fig. 1), and with no effect of age group. 
Significant improvements also were seen on the Social Responsiveness Scale, the CY-BOCS-
PDD, the ADHD-IV Rating Scale, and the other subscales of the ABC, except for the 
Inappropriate Speech subscale, which showed marginal change (Table 3). An increase was noted 
on the Vineland-Communication domain standard score, and a marginal increase on the Vineland 
Adaptive Behavior Composite Score, but not on the other domains of the Vineland or on the 
Leiter-R (data not shown). 
Fig. 1 
Aberrant Behavior Checklist subscale scores by study week. Scores on the irritability and the 
social withdrawal subscales are shown. Error bars indicate standard error of the mean 
 
Table 3 
Efficacy results 
Measure Baseline Week 8 p value 
ABC-Irritability 27.0 ± 7.61 17.7 ± 10.35 <0.001 
ABC-Lethargy/Social withdrawal 17.3 ± 8.18 12.6 ± 89.30 0.001 
ABC-hyperactivity 29.7 ± 12.14 21.1 ± 12.01 <0.001 
ABC-inappropriate speech 7.0 ± 3.53 6.0 ± 4.04 0.081 
ABC-stereotypy 9.3 ± 6.77 6.6 ± 6.90 0.002 
Social responsiveness scale (total 
score) 117.0 ± 33.75 103.0 ± 29.62 0.037 
CY-BOCS-PDD 14.8 ± 4.12 11.6 ± 4.95 <0.001 
ADHD-IV rating scale (total score) 34.2 ± 11.38 26.1 ± 12.95 <0.001 
CASI-anxiety 20.4 ± 10.56 16.5 ± 13.79 <0.001 
CGI-I – 2.5 ± 0.92 – 
CGI-S 5.1 ± 0.91 4.4 ± 1.16 – 
In addition to the improvements in specific aberrant and functional behaviors, improvements 
were observed on the clinician-rated CGI-I and the CGI-S global assessments (Table 3). At Week 
8, CGI-S scores had improved in 14 subjects (50 % of those with data available), worsened in 2, 
and were unchanged in 12. On the CGI-I, 20 subjects (71.4 % of those with data) had Week 8 
scores of “1”(“very much improved”) or “2” (“much improved”), scores that are generally felt to 
reflect clinically meaningful change. Thirteen (13) subjects (41 %) were classified as 
“responders” in the domain of social function, according to a rigorous post hoc definition, 
requiring improvement of at least 25 % on the ABC-Social Withdrawal score and a CGI-I score 
of “very much” or “much improved.” 
Discussion 
Over the past two decades, the majority of ASD medication trials have tested agents that are 
approved for use in other neuropsychiatric disorders, such as psychosis, depression, anxiety, and 
ADHD, but that have uncertain mechanistic relevance to ASD. Some of these medications have 
clear value in the management of interfering symptoms and behaviors associated with ASD. 
Improvements in social behaviors have been noted in some trials, though these findings often 
derive from secondary analyses [e.g., studies of risperidone (Scahill et al. 2012)], or are from 
open-label studies, (Aman et al. 2009) or are from populations with specific comorbidity [e.g., 
hyperactivity in trials of methylphenidate and guanfacine (Scahill et al. 2006; Jahromi et al. 
2009)]. By contrast, few studies have prospectively aimed to demonstrate an impact on the core 
social and communicative symptoms of ASD. The emerging cellular- and molecular-level 
mechanistic understanding of ASD is leading to the development and testing of compounds 
focused on core deficits. In the open-label study reported here, STX209, a GABA-B agonist 
selected to reduce the hypothesized excessive glutamatergic and deficient GABAergic signaling 
in ASD, showed beneficial effects on measures of irritability, social function and communication, 
as well as on global improvement. These results are consistent with the hypothesis that 
modulation of cell signaling pathways that are perturbed in fragile X syndrome may be relevant 
to other cases of ASD as well. 
The improvement seen on the ABC-Irritability subscale, the primary endpoint of this open-label 
study, suggests that STX209 may have efficacy in the same domain for which risperidone and 
aripiprazole have proven efficacy. The baseline ABC-Irritability scores for subjects in this study 
were comparable to those reported in the prior pivotal trials of risperidone and aripiprazole. 
Although the degree of improvement observed during open-label STX209 treatment here (ABC-I 
decrease of 34 %) was less than that seen in the initial risperidone controlled study (decrease of 
57 %), it was more similar to that found in the aripiprazole flexible-dose study (decrease 44 %). 
Subjects also showed significant improvement on the ABC-Lethargy/Social Withdrawal subscale 
(ABC-LSW), which assesses aspects of social avoidance and motivation. STX209 was associated 
with a reduction in ABC-LSW scores of 27 % from baseline. We note that the subjects in this 
study were children and adolescents with ASD who had significant levels of irritability, as in 
previous trials of atypical antipsychotics for ASD. In a controlled study of risperidone, a 
significant group effect was seen, with a decrease of 46 % on risperidone versus 26 % on placebo. 
An open-label risperidone trial showed reductions of 59 and 69 % for medication-only and 
medication + parent training, respectively. A reduction of 44 % was seen in the flexibly-dosed 
aripiprazole study, but this change was not significantly different than in the placebo-treated 
group. In addition, we observed parallel improvements on the Social Responsiveness Scale, 
which provides a wide-ranging assessment of social behaviors and social cognitive ability, and on 
the Vineland Communication subscale, adding convergent validity to changes seen in ABC-LSW 
ratings. Although the overall magnitude of improvements in ABC-SW with STX209 are not 
greater than those seen in other treatment studies of children with ASD accompanied by serious 
behavioral problems, these results offer the first empirical findings and some support for the role 
of GABAergic treatments in ASD. These data support additional, larger-scale, controlled studies 
with STX209 or other GABAergic compounds. Studies in subjects with lower levels of irritability 
will be needed to determine whether the effects in the social domain are primary or are secondary 
to reductions in irritability. 
The results of this study are limited primarily by its open-label design. This is of particular 
importance in ASD research in which there is a long history of positive open-label findings 
focused on core impairments followed by negative results in subsequent placebo-controlled trials 
(D. J. Posey et al. 2008). Placebo effects are evident in virtually all neuropsychiatric trials, and 
trials in ASD are no exception, as found in the studies of aripiprazole and citalopram. We note 
that in the earlier randomized, controlled trial of STX209 for patients with FXS, STX209 was not 
associated with greater improvement than placebo on the ABC-Irritability subscale. Placebo 
effects historically have been the highest in ASD trials focused on core social impairment with 
placebo response rates in the 30–40 % range noted (D. Posey et al. 2009). Our reliance on parent-
report measures in this trial of a novel compound may have increased expectancy bias. Thus, we 
acknowledge that the broad improvements found on essentially all of the behavior rating scales 
may reflect such a general placebo effect. Alternatively, it may be possible that effective 
treatment of the core pathophysiology of ASD could result in broad symptomatic improvement. 
Even assuming that STX209 is effective for core pathophysiology in ASD, the smaller or non-
significant improvements in functional and cognitive measures in this study may be the 
consequence of the relatively short 8-week duration of treatment, and the need for longer-term 
educational/behavioral intervention in combination with pharmacotherapy to effect change in 
these parameters. It is notable also that only 41 % of the subjects met rigorous criteria in the 
responder analysis. This raises questions about the symptom target, entry criteria and duration of 
future trials. For example, given the recognized heterogeneity of ASD, future trials may enroll 
distinct subpopulations to test new treatments. The ABC-LSW scale has now demonstrated 
reliability, validity and sensitivity to change in the open-label context of the current study. 
However, it may be argued that it targets a relatively narrow domain of social disability in a 
disorder characterized by a broad range of social deficits. 
Some subjects in this study exhibited a worsening of underlying symptoms such as agitation, 
irritability, and aggression. Although it is possible that these events represent a deleterious drug 
effect, many of these events may reflect spontaneous variability in underlying symptoms. This 
interpretation is consistent with the results of a placebo- controlled study of STX209 in FXS, in 
which rates of adverse events such as irritability and aggression were higher on placebo than on 
STX209. Other adverse events in this study did not present significant clinical concerns, and the 
relative lack of sedation and somnolence contrast with the well-known tolerability profile of 
racemic baclofen. 
A placebo-controlled trial of STX209 is needed to determine whether the beneficial effects on 
irritability and social behavior seen in this study will be superior to placebo. Placebo comparison 
also provides a more rigorous evaluation of adverse events and 
overall safety. Regardless of the results for STX209, however, the development of treatments 
based on the increasingly more refined neurobiological understanding of ASD holds the strongest 
hope for identifying new therapies that target disease pathophysiology and potentially alter the 
developmental trajectory of patients at risk for or affected by ASD. 
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